{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:36:17Z","timestamp":1790379377589,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health USA","doi-asserted-by":"publisher","award":["CA210065"],"award-info":[{"award-number":["CA210065"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.beha.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T22:43:58Z","timestamp":1539729838000},"page":"361-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Can one target T-cell ALL?"],"prefix":"10.1016","volume":"31","author":[{"given":"Adolfo","family":"Ferrando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2018.10.001_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrc.2016.63","article-title":"The genetics and mechanisms of T cell acute lymphoblastic leukaemia","volume":"16","author":"Belver","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2018.10.001_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2018.10.001_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2018.10.001_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.beha.2018.10.001_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOH.0b013e3283623c61","article-title":"Early T-cell precursor acute lymphoblastic leukaemia","volume":"20","author":"Haydu","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.beha.2018.10.001_bib6","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1084\/jem.20112239","article-title":"ETV6 mutations in early immature human T cell leukemias","volume":"208","author":"Van Vlierberghe","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2018.10.001_bib7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ng1425","article-title":"Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia","volume":"36","author":"Graux","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2018.10.001_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2008-12-192039","article-title":"WT1 mutations in T-ALL","volume":"114","author":"Tosello","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.10.001_bib9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.2246","article-title":"The TLX1 oncogene drives aneuploidy in T cell transformation","volume":"16","author":"De Keersmaecker","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3324\/haematol.2011.059030","article-title":"The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia","volume":"97","author":"Zuurbier","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2018.10.001_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2018.10.001_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(04)15542-6","article-title":"Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia","volume":"363","author":"Ferrando","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2018.10.001_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.15449","article-title":"The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols","volume":"182","author":"Paganin","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2018.10.001_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.beha.2018.10.001_bib15","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.0606108103","article-title":"NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth","volume":"103","author":"Palomero","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2018.10.001_bib16","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/nm.3955","article-title":"Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia","volume":"21","author":"Herranz","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2016-09-692582","article-title":"The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia","volume":"129","author":"Sanchez-Martin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.10.001_bib18","series-title":"The role of NOTCH1 signaling in T-ALL","first-page":"353","author":"Ferrando","year":"2009"},{"key":"10.1016\/j.beha.2018.10.001_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1074-7613(00)80054-0","article-title":"Deficient T cell fate specification in mice with an induced inactivation of Notch1","volume":"10","author":"Radtke","year":"1999","journal-title":"Immunity"},{"issue":"Suppl 3","key":"10.1016\/j.beha.2018.10.001_bib20","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.3816\/CLM.2009.s.013","article-title":"Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia","volume":"9","author":"Palomero","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.beha.2018.10.001_bib21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1158\/1535-7163.MCT-11-0938","article-title":"Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia","volume":"11","author":"Samon","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2018.10.001_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib23","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1073\/pnas.1611831114","article-title":"Synergistic antileukemic therapies in NOTCH1-induced T-ALL","volume":"114","author":"Sanchez-Martin","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2018.10.001_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nm1524","article-title":"Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia","volume":"13","author":"Vilimas","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib25","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1182\/blood-2008-02-136762","article-title":"Targeting the Notch1 and mTOR pathways in a mouse T-ALL model","volume":"113","author":"Cullion","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.10.001_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/15384101.2015.1128191","article-title":"Targeting NOTCH1 in T-ALL: starving the dragon","volume":"15","author":"Herranz","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.beha.2018.10.001_bib27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2018.10.001_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2013-03-491092","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.10.001_bib29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2018.10.001_bib30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib31","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4161\/cc.7.8.5753","article-title":"The role of the PTEN\/AKT Pathway in NOTCH1-induced leukemia","volume":"7","author":"Palomero","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.beha.2018.10.001_bib32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ni1234","article-title":"Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism","volume":"6","author":"Ciofani","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beha.2018.10.001_bib33","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.10.001_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccr.2012.02.029","article-title":"Targeting nonclassical oncogenes for therapy in T-ALL","volume":"21","author":"Subramaniam","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2018.10.001_bib35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.ccr.2013.10.022","article-title":"Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia","volume":"24","author":"Piovan","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2018.10.001_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2018.10.001_bib37","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.10.001_bib38","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.20110580","article-title":"Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias","volume":"208","author":"Shochat","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2018.10.001_bib39","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2018.10.001_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood-2017-07-797597","article-title":"Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL","volume":"131","author":"Degryse","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.10.001_bib41","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.10.001_bib42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2017.276","article-title":"Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK\/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia","volume":"32","author":"Degryse","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2018.10.001_bib43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2008.80","article-title":"Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2018.10.001_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/leu.2008.318","article-title":"Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia","volume":"23","author":"Deenik","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2018.10.001_bib45","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.leukres.2011.03.025","article-title":"NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse","volume":"35","author":"Clarke","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2018.10.001_bib46","first-page":"3979","article-title":"Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: a case report","volume":"14","author":"Chen","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.beha.2018.10.001_bib47","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1608420113","article-title":"Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia","volume":"113","author":"Oshima","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2018.10.001_bib48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","article-title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia","volume":"45","author":"Meyer","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2018.10.001_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.06.003","article-title":"Structure and mechanisms of NT5C2 mutations driving thiopurine resistance in relapsed lymphoblastic leukemia","volume":"34","author":"Dieck","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2018.10.001_bib51","doi-asserted-by":"crossref","first-page":"17828","DOI":"10.1074\/jbc.M700917200","article-title":"Crystal structure of human cytosolic 5'-nucleotidase II: insights into allosteric regulation and substrate recognition","volume":"282","author":"Wallden","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2018.10.001_bib52","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nature25186","article-title":"Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia","volume":"553","author":"Tzoneva","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.beha.2018.10.001_bib53","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2018.10.001_bib54","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib55","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4458","article-title":"Targeted cellular immunotherapy for T cell malignancies","volume":"23","author":"Palomero","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2018.10.001_bib56","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-15-0675","article-title":"Triggering the TCR developmental checkpoint Activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia","volume":"6","author":"Trinquand","year":"2016","journal-title":"Cancer Discov"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:04:49Z","timestamp":1761498289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521692618300902"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.10.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can one target T-cell ALL?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}